Fig. 1: High CHK1 expression correlates with MYCN status and predicts clinical outcome in neuroblastoma patients.
From: A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors
A–D Data analyses on the SEQC-498-RPM dataset performed on the R2-Genomics platform. Box plots of CHK1 mRNA expression relative to MYCN status (A) and risk classification (B). Kaplan–Meier curves reporting overall survival with respect to CHK1 mRNA expression in neuroblastoma patients (C) and in the non-MNA subset (D). The last quartile modus was used for cut-off determination with a minimum group size of 8 to determine the best p values. E Western blot (WB) analysis of whole cell lysates from the indicated non-MNA and MNA cell lines. Blots were probed with the indicated antibodies; β-actin was used as loading control. F Bar plot representing the mean CHK1 protein expression (+SD) in non-MNA and in MNA cells. Densitometry was performed using ImageJ software (ver. 1.51j8). *p < 0.05. p value was calculated by a two-sided Student’s t test.
